Alpha-9’s Approach

Distinctive approach to building best-in-class molecules

Our approach

Alpha-9 follows a systematic approach to developing radiopharmaceuticals, supported by state-of-the-art infrastructure. After selecting a target, Alpha-9’s core competency lies in designing bespoke molecules with high tumor-specific uptake and excellent stability.

Target selection

Alpha-9 works with extracellular targets that are overexpressed in tumor cells

Molecule design

Alpha-9 optimizes each component of the molecule: binder, chelator, linker, and isotope. Alpha-9’s binders can be peptides, small molecules, or biologics

Formulation

Formulation is non-trivial as the radiolabeled molecule is continuously subject to radiolysis. Alpha-9 targets a week-long shelf-life for its final products

Clinic

Alpha-9 is currently running multiple clinical trials across the world against multiple targets and indications

Molecule design

Alpha-9’s molecules comprise four components – binder, linker, chelator, and radioisotope – which are optimized in a bespoke, iterative process.

Infrastructure

Alpha-9 has custom-built research facilities in Vancouver, which are equipped for biology, chemistry, in vitro and in vivo radiochemistry work, formulation, and are licensed for a diverse array of radioisotopes. This robust infrastructure is critical for generating high-quality data and accelerating the development of promising molecules from concept to clinic.

Pipeline

Alpha-9 has a portfolio of programs in the clinic and robust set of preclinical programs across a range of targets and tumor indications.

We have established partnerships with multiple organizations and academic institutions. If you are interested in learning more about strategic collaborations or partnership opportunities, please reach out to the Business Development team at: BD@a9oncology.com.